r Medullo-spinal CSF contacting neurones (CSF-cNs) located around the central canal are conserved in all vertebrates and suggested to be a novel sensory system intrinsic to the CNS.
Introduction
GABA B receptors (GABA B -Rs) belong to family 3 (or family C) G-protein coupled receptors and mediate the slow inhibitory response to GABA by activating G i/o protein-dependent signalling pathways (Padgett & Slesinger, 2010; Pinard et al. 2010) . The core structure of GABA B -Rs consists of two principal subunits, GABA B1 and GABA B2 that assemble into heteromeric functional receptors at pre-and postsynaptic sites of the synapse (Möhler & Fritschy, 1999; Bettler et al. 2004; Pin & Bettler, 2016) . Presynaptic GABA B -Rs are positioned at axon terminals of both excitatory (heteroreceptors) and inhibitory (autoreceptors) neurones, where their activation suppresses neurotransmitter release through inhibition of voltage-dependent calcium channels (Ca V ), although other mechanisms have been implicated (Scanziani et al. 1992; Chen & van den Pol, 1998; Barral et al. 2000; Sakaba & Neher, 2003) . Postsynaptic GABA B -Rs are expressed in somatodendritic compartments of neurones and evoke a slow inhibitory postsynaptic current by gating G protein-coupled inwardly rectifying potassium (GIRK) channels, which hyperpolarises the membrane and inhibits neuronal excitability (De Koninck & Mody, 1997; Lüscher et al. 1997) . Postsynaptic GABA B -Rs additionally down-regulate Ca V channels, thus controlling calcium-dependent neuronal processes such as dendritic Ca 2+ -spike propagation and synaptic plasticity (Pérez-Garci et al. 2006; Booker et al. 2018) . Finally, GABA B -Rs can influence pre-and postsynaptic functions by inhibiting adenylyl cyclase, though the physiological consequences of this modulation are poorly understood (Padgett & Slesinger, 2010) . In addition to their diverse signalling pathways, GABA B -Rs are widely expressed throughout the central nervous system including the hindbrain and the spinal cord, thereby playing pivotal roles in numerous physiological processes (Margeta-Mitrovic et al. 1999; Bettler et al. 2004) .
Medullo-spinal neurones that contact the cerebrospinal fluid (CSF-cNs) constitute a peculiar neuronal population located around the central canal (CC) of all vertebrates (Vígh et al. 2004; Djenoune et al. 2014) . They feature a bipolar morphology with a short dendritic process projecting toward the CC and ending in its lumen with a terminal protrusion or 'bud' , suggesting a role in sensing CSF flow or composition (Stoeckel et al. 2003; Marichal et al. 2009; Orts-Del'Immagine et al. 2012 . Consistent with this hypothesis, CSF-cNs express selectively the polycystic kidney disease 2-like 1 (PKD2L1) channel, a sensory transduction protein sensitive to extracellular variation of pH and osmolarity and sensing CSF flow and spinal cord torsion (Huang et al. 2006; Orts-Del'Immagine et al. 2012 Böhm et al. 2016; Jalalvand et al. 2016) . PKD2L1 channels are non-selective cationic channels that produce enough depolarisation to trigger action potentials and therefore they contribute to setting the excitability of CSF-cNs (Orts-Del' Immagine et al. 2012 Immagine et al. , 2016 . Moreover, CSF-cNs are embedded in a neuronal network, receiving primarily inhibitory synaptic inputs from yet-unidentified presynaptic partners (Orts-Del'Immagine et al. 2012) . Inhibition of CSF-cNs was shown to be mediated by the amino acids GABA and glycine, which activate ionotropic GABA A and glycine receptors, respectively (Marichal et al. 2009; Orts-Del'Immagine et al. 2012) . In addition, previous immunohistochemical studies revealed the presence of GABA B -Rs in neurones of rat spinal cord surrounding the central canal and with morphological properties of CSF-cNs (Margeta-Mitrovic et al. 1999) . However, their function, as well as their signalling effectors in CSF-cNs, remain unknown.
In the present study, we assessed the expression and functional properties of GABA B -Rs in CSF-cNs of the mouse brainstem. Double immunohistofluorescence staining with the selective marker PKD2L1 for CSF-cNs show that the GABA B1 subunit localises in the soma and the dendrite of medullar CSF-cNs. Using patch-clamp recordings and calcium imaging we demonstrate that postsynaptic GABA B -Rs in CSF-cNs function by inhibiting Ca V channels through recruitment of Gβγ but surprisingly they do not activate GIRK channels in these neurones. CSF-cNs in the mouse brainstem were initially thought to be under the sole control of inhibitory synaptic inputs, but here, using an electrical stimulation protocol, we demonstrate that CSF-cNs also receive glutamatergic excitatory inputs involving AMPA/kainate receptors. Finally, we show that GABA B -Rs, presumably localised on both GABAergic and glutamatergic terminals, have an inhibitory action on GABA and glutamate release onto CSF-cNs.
Methods

Animal ethics
All experiments were conducted in conformity with the rules set by the EC Council Directive (2010/63/UE) and the French 'Direction Départementale de la Protection des Populations des Bouches-du-Rhône (DDPP13) ' (Licence No. 13 .435 held by J. T. and No. 13.430 by N.W.). Experiments were performed using 98 C57BL/6J mice (Mus musculus) of both sexes aged 8-18 weeks old (25-30 g, obtained from Envigo, Gannat, France). All animals were housed at constant temperature (21°C), in an enriched environment, under a standard 12 h light-12 h dark cycle, with food (pellet AO4, UAR, Villemoisson-sur-Orge, France) and water provided ad libitum. Every precaution was taken to reduce to the minimum the number of animals used and to minimise animal stress during housing and prior to experiments. We understand the ethical principles under which The Journal of Physiology operates, and our work complies with the journal's animal ethics checklist.
Histological procedures and confocal imaging
Adult mice were anaesthetised intraperitoneally with a combination of 100 mg kg -1 ketamine (Carros, France) and 15 mg kg −1 xylazine (Puteau, France). Animals were then transcardially perfused first with 0.1 M PBS and then by 4% paraformaldehyde in PBS (PFA; Sigma-Aldrich). Tissues were immediately removed, post-fixed for 30 min to 1 h in PFA at room temperature followed by overnight washing in PBS at 4°C. Tissues were finally cryoprotected for 24-48 h in 30% sucrose in PBS at 4°C and frozen in isopentane (−40°C). Coronal brainstem thin sections (40 μm) were obtained using a cryostat (Leica CM3050, Wetzlar, Germany) and collected serially in twelve-well plates containing 0.1 M PBS. Sections were then incubated for 1 h in PBS containing 0.3% Triton X100 (Sigma-Aldrich) and 2% donkey serum with 1% bovine serum albumin (BSA), followed by an overnight incubation at 4°C with rabbit anti-PKD2L1 IgG (1:700; AB9086, Millipore-Chemicon, Fontenay-sous-Bois, France) and then a 24 h incubation at room temperature with mouse anti-GABA B1 IgG (1:100, AB55051, Abcam Biomedicals, Paris, France). Sections were then washed in PBS and incubated for 2 h with secondary antibodies conjugated to either AlexaFluor 488 (PKD2L1: 1:400; Millipore-Chemicon) or 594 (GABA B1 : 1:1000; Millipore-Chemicon). Sections were mounted on gelatine-coated slides and coverslipped with home-made mowiol mounting medium for fluorescence microscope examination. Confocal images were captured with a Zeiss LSM 700 laser scanning microscope before processing with ZEN 2009 light Edition (Zeiss, Iena, Germany) and ImageJ 1.8.0 software (NIH).
Acute brainstem slice preparation
Coronal brainstem slices (from the caudal part up to the 4th ventricle) were prepared as previously described by (Orts-Del'Immagine et al. 2012) . Briefly, 8-to 12-week-old mice were anaesthetised with the ketamine-xylazine solution, decapitated, and the brain rapidly removed and submerged in ice-cold (0-4°C), oxygenated (95% O 2 -5% CO 2 ) and low calcium-high magnesium cutting solution containing (in mM): NaCl 75, NaHCO 3 33, NaH 2 PO 4 1.25, KCl 3, CaCl 2 0.5, MgCl 2 7, glucose 15, sucrose 58, ascorbic acid 2, sodium pyruvate 2, myo-inositol 3 (pH 7.3-7.4; osmolality 300-310 mosmol kg −1 ). Coronal brainstem slices (250 μm thick) were cut with a vibratome (Leica VT1000S) and incubated for 15-20 min at 35°C in a submerged chamber filled with oxygenated artificial CSF (aCSF) containing (in mM): NaCl 115, NaHCO 3 23, NaH 2 PO 4 1.25, KCl 3, CaCl 2 2, MgCl 2 2, glucose 15, ascorbic acid 2, sodium pyruvate 2, myo-inositol 3 (pH 7.3-7.4; osmolality 300-310 mosmol kg −1 ). Slices were then maintained in oxygenated aCSF at room temperature prior to recording. After a recovery period of at least 1 h, slices were transferred to the recording chamber superfused with aCSF at 1.5-2.5 ml min −1 .
Electrophysiology
Neurones around the central canal were visualised under infrared illumination using oblique or DIC optics mounted on a Scientifica SliceScope Pro 1000 or Zeiss Axioscope S1 microscope, respectively. Whole-cell patch-clamp recordings were performed at room temperature (ß20°C) in current-and/or voltage-clamp et al. 2012, 2016) . Series resistance (10-20 M ) was monitored throughout each experiment and unstable recordings were discontinued. For voltage-gated calcium currents recordings, series resistance was compensated by 70-80%. Data were filtered at 2-2.4 kHz and digitised at 10 kHz using a Digidata 1322A or 1440A interface (Molecular Device) driven by pClamp 9.2 or 10.7, respectively (Molecular Device). The liquid junction potential was left uncorrected.
Recording of voltage-gated calcium currents. For the characterisation of postsynaptic voltage-gated calcium (Ca 2+ ) channels (Ca V ) and the study of their modulation by GABA B -Rs, electrodes were filled with a solution containing (in mM): CsCl 3, caesium acetate 100, NaCl 5, MgCl 2 1, CaCl 2 1, TEA-Cl 20, EGTA 10, HEPES 10, disodium phosphocreatine 10, Mg-ATP 4, Na 3 GTP 0.2 (adjusted to pH 7.36 with CsOH; osmolality of 290-295 mosmol kg −1 ). Calcium currents were elicited by 100-200 ms voltage steps (V Step , 10 mV increments) from a holding potential of −70 mV while the neurone was perfused with oxygenated aCSF supplemented with 10 μM gabazine (GABA A receptor antagonist), 1 μM strychnine (glycine receptor antagonist), 0.5 μM tetrodotoxin (TTX, inhibitor of sodium channels) and 20 mM tetraethylammonium chloride (TEA-Cl, blocker of potassium channels). The current-voltage relationship was constructed for each cell by plotting the Ca 2+ peak current recorded for a given V Step and the properties and voltage-dependence of Ca 2+ current were analysed with a Boltzmann fit using the following equation:
where I represents the current amplitude as a function of voltage (V), g max is the maximum whole-cell channel conductance, V rev is the current reversal potential, V 50 is the voltage for half-maximal channel activation and k (the slope) is equal to RT/z g F where z g is the valency of the voltage sensor of the calcium channel.
Calcium current inhibition by postsynaptic GABA B -Rs was assessed on Ca 2+ peak current (elicited with a 100 ms V Step to +10 mV every 30 s over a 10 min period) by application of baclofen (100 μM, 30 s), a selective agonist for GABA B -Rs, using a pressure application pipette (ß1 μm tip diameter) positioned at ß50 μm from the recorded cells and connected to a pressure application system (Toohey Company, Hollis, NH, USA). The molecular mechanism by which GABA B -R activation modulates Ca 2+ currents was studied with a triple-pulse voltage protocol (recorded every 30 s for 10 min) consisting of two 50 ms test pulses to +10 mV from a holding potential of −70 mV, separated by a 50 ms conditioning pulse to +100 mV. The inhibition of calcium currents induced by application of baclofen was then compared before (prepulse) and after (postpulse) the large depolarising conditioning pulse (Herlitze et al. 1996; Ikeda, 1996) .
Recording of inwardly rectifying (GIRK/Kir3) potassium currents. To record postsynaptic GABA B -mediated Kir3-type K + currents (GIRK), patch pipettes were filled with a solution containing (in mM): potassium gluconate 140, NaCl 4, HEPES 5, MgCl 2 2, EGTA 1.1, Na 2 ATP 2, disodium phosphocreatine 5, Na 3 GTP 0.6 (adjusted to pH 7.35 with KOH; osmolality 285 mosmol kg − 1). Kir3-type K + currents were evoked by pressure application of baclofen (100 μM, 40 s) at −50 mV in the presence of 10 μM gabazine, 1 μM strychnine and 20 μM DNQX (AMPA/kainate receptor antagonist).
Recording of synaptic currents. Electrically evoked inhibitory (IPSCs) and excitatory (EPSCs) postsynaptic currents were recorded with patch electrodes filled with (in mM): CsCl 130, NaCl 4, MgCl 2 2, EGTA 1.1, HEPES 1.1, disodium phosphocreatine 5, Na 2 ATP 2, Na 3 GTP 0.6, lidocaine N-ethyl chloride 5 (adjusted to pH 7.35 with CsOH; osmolality 285 mosmol kg −1 ). IPSCs and EPSCs were elicited at 0.1 Hz by voltage pulses with a stimulus isolator (100 μs, 50-60 V stimuli; ISO-Flex, A.M.P.I, Jerusalem, Israel) through a stimulating electrode filled with aCSF and positioned at 50-100 μm from the soma of the recorded cell. GABA A receptor-mediated IPSCs were recorded at −60 mV and were isolated by including 1 μM strychnine and 20 μM DNQX to the external solution. To record glutamatergic receptor-mediated EPSCs, the external solution was supplemented with 1 μM strychnine and 10 μM gabazine. EPSCs were recorded at holding potential of −60 mV. GABA B -R-mediated inhibition of IPSCs and EPSCs was assessed by bath application of baclofen (20 or 100 μM, see Results). For paired-pulse ratio analysis, stimuli were delivered in pairs with 70 ms interpulse intervals and a frequency of 0.1 Hz.
Calcium imaging
Calcium imaging experiments were performed in CSF-cNs patched with electrodes containing (in mM): KCl 3, potassium gluconate 120, NaCl 5, MgCl 2 1, CaCl 2 0.25, EGTA 2, HEPES 10, disodium phosphocreatine 10, Mg-ATP 4, Na 3 GTP 0.2 (adjusted to pH 7.33 with KOH; osmolality 290-295 mosmol kg −1 ). Cells were loaded with the fluorescent Ca 2+ probe Fluo-4 (50 μM, Invitrogen, Carlsbad, CA, USA) through the patch pipette and the preparation was illuminated (490 nm, excitation bandpass filter: 490 ± 30 nm; Chroma, Bellows Falls, VT, USA) using the CoolLED epifluorescence system (p1 PrecisExcite, Andover, UK), The emitted light (520 nm, emission bandpass filter: 535 ± 30 nm and a dichroic mirror set at 515 nm; Chroma) was collected with a HQ2 CoolSnap CCD camera (Standard mode at 10 MHz and Gain 1, Photometrics) connected to a PC through a frame grabber (CoolSNAP LVDS interface card, Photometrics, Tucson, AZ, USA) and controlled by MetaView software (Molecular Devices). To optimise imaging conditions and reduce fluorescence quenching, a square region of interest (ROI) was drawn around the recorded neurones, the illumination intensity was set at 25% of the maximum power. Images were acquired in time laps mode with 2 × 2 binning for 100 ms every 0.2 s over a 1 min period (151 images). CSF-cNs were recorded in current-clamp mode from the resting membrane potential (RMP) and after a period of baseline recording, 5 consecutive trains of action potentials (APs) (0.5 Hz) were triggered with a 500 ms DC current pulse (+20 pA) to induce Ca 2+ influx following membrane depolarisation and monitor the elicited elevation in intracellular Ca 2+ . To test whether the Ca 2+ elevations were effectively mediated through Ca V activation, recordings were also carried out in voltage-clamp mode with an intracellular solution containing (mM): CsCl 3, caesium acetate 100, NaCl 5, MgCl 2 1, CaCl 2 1 TEA-Cl, 20, EGTA 2, HEPES 10, disodium phosphocreatine 10, Mg-ATP 4, Na 3 GTP 0.2, with 50 μM Fluo-4 (adjusted to pH 7.36 with CsOH; osmolality 290-295 mosmol kg −1 ). CSF-cNs were depolarised to +10 mV for 100 ms from a holding potential set at −70 mV and the increase in fluorescence simultaneously recorded.
Reagents
All reagents were purchased from Sigma-Aldrich except: Tetrodotoxin (TTX) from Latoxan (Portes-lés-Valence, France). 6,7-dinitroquinoxaline-2,3-dione disodium salt (DNQX) from Abcam Biochemicals. (R)-baclofen and gabazine (SR 95531) from Tocris Bioscience (Bristol, UK). ω-conotoxin GVIA, ω-agatoxin IVA and nifedipine from Alomone labs (Jerusalem, Israel). CGP54626A (CGP) was a gift from Bernhard Bettler (University of Basel, Switzerland) and was initially produced by Novartis Pharma AG (Basel, Switzerland).
Data analysis and statistics
Data analysis. Current and potential responses were analysed using the Clampfit 10 suite (Molecular Devices Inc.) and Excel 2016 (Microsoft). In our analysis, the peak and the mean amplitudes were considered for current and voltage responses, respectively (see below). The RMP was determined in current-clamp mode at I = 0 just after the whole-cell configuration was achieved as well as by averaging in the current-clamp recordings a ß1 s period in the absence of action potentials (APs) and of current injection (I injection = 0 pA). AP properties were analysed either from recordings of the spontaneous discharge activity (10-30 s periods) or from trains of APs elicited by the injection of a +20 pA DC current pulse for 500 ms using the 'threshold detection' routine from Clampfit 10 with a threshold set at 0 mV. In each condition, the principal parameters of APs (amplitude, overshoot, 10-90% rise time and level of after hyperpolarisation) were determined, as well as AP frequency.
Over the period used to record Ca 2+ current (ß10 min) we consistently observed a decrease in the Ca 2+ current amplitude, known as rundown (see Discussion). Therefore, to account for this phenomenon when comparing Ca 2+ current amplitude over time, we fitted the baseline data points (control) before drug application (Ca 2+ channel blockers, toxins or baclofen) recorded for each cell with a linear regression function (y = ax + b; where y and x are the recorded peak current and time, respectively, and a and b are constants). The current amplitude in the presence of the drug was measured from the raw data and compared to the value in control calculated at the same time points from the linear regression; this procedure avoided an overestimation for the degree of inhibition.
To measure changes in fluorescence, i.e. intracellular calcium concentrations ([Ca 2+ ] i ), regions of interest (ROI) were drawn over the CSF-cN soma (ROI Cell, Fig. 5A ) and the background (ROI Bkg, Fig. 5A ) on the recorded images. The average fluorescence intensity was measured over time from these two ROIs and subsequently, the background fluorescence intensity was subtracted from the somatic data to compute the net fluorescence (F). The average fluorescence intensity before stimulus application (Ca V activation or train of APs), the so-called basal intensity or F 0 , was then calculated over 30-40 images. Finally, the net rise from baseline in cell fluorescence was calculated as the (F − F 0 )/F 0 or F/F 0 ratio and expressed as a percentage. The average fluorescence intensity was then plotted over time to illustrate Ca 2+ transients and the peak amplitude of the fluorescence rise measured and compared between the control and the test situations. Fluorescence signal when using imaging with epifluorescence and diffusion of Fluo-4 into the cell through the patch pipette exhibits a progressive decrease in intensity over time, a phenomenon known as fluorescence bleaching or quenching. We therefore computed the amount of quenching over time by fitting the baseline data with a linear regression function (y = ax + b; where y and x are the F/F 0 value and J Physiol 597.2 time, respectively, and a and b are constants) and subtracted these data from the raw data points in a point to point manner. To compare the amplitude of the rise in fluorescence, in control vs. baclofen, the maximum amplitude recorded after the 5 th train of APs was normalised against that of the 1st train for each recording.
The inhibitory effect of GABA B -R activation on IPSCs and EPSCs was determined by comparing current amplitudes of 30 averaged traces including failures before and during application of baclofen or CGP. The paired-pulse ratio (PPR) was calculated as the ratio of the second postsynaptic current (PSC) over the first PSC. The decay times of EPSCs and IPSCs were obtained by fitting the decay phase of the current with a single exponential equation using Clampfit 10. Rise times (10-90%) of synaptic currents were calculated using the statistics tool of Clampfit 10. In all figures showing EPSCs and IPSCs, stimulus artifacts were blanked for clarity.
Statistical analysis. Data were expressed as means ± SD in text and represented as box-whisker plot using Tukey's method with Prism 6 (GraphPad) software or RStudio 1.1.456 (R Studio Team, 2018), as previously described (Orts-Del' Immagine et al. 2017) . Briefly, for each data set, the median and the 25 th to the 75 th percentiles (lower and upper limits of each bar, respectively) are calculated. Next, the interquartile distance (IQR) is determined as the difference between the 25 th and 75 th percentiles and the whiskers limits or 'inner fences' calculated as the 75 th percentile plus 1.5 times IQR and the 25 th percentile minus 1.5 times IQR. All data with values either higher or lower than the inner fences are represented as individual data points and considered as outliers. In all the figures where data are presented with box-and-whiskers plots, the thick horizontal line represents the median. For all electrophysiological data and histological experiments, n refers to the number of recorded cells and to the number of mice exanimated, respectively. All data were tested for normal distribution using the Shapiro-Wilk test with Prism 6 software or R statistics. Data with normal distributions were analysed with a one-way ANOVA followed by Tukey's multiple comparison post hoc test for the statistical comparison of multiple groups or with a Student's two-tailed paired t test for the comparison of two groups (Prism 6, GraphPad, La Jolla, CA, USA). Data without normal distributions were analysed with a Friedman or Kruskal-Wallis test followed by a post hoc Dunn's multiple comparisons test when comparing multiple groups; Mann-Whitney or Wilcoxon matched-pairs signed rank test when comparing two groups (Prism 6, GraphPad or R statistics).
For the statistical analysis of Ca 2+ current blockade (use of blockers or toxins) and modulation by baclofen, as well as the reduction in the level of intracellular calcium elevation following activation of GABA B -Rs, we had to consider dependent (data within a group) and independent (data between groups) variables. For a given cell, the measured parameter or variable (current amplitude or Ca 2+ elevation) and its inhibition/ modulation by a drug is considered as a variable dependent on the condition (baseline or drug) within a given group while the same variable represents an independent factor when considered between different groups (control and drug of different types). Therefore, the statistical analyses require the use of a mixed effect model considering in a hierarchical way both dependent and independent variables. The drug effects within a group and between different groups on the analysed variable represent fixed factors (Condition and Group). Finally, because the choice of the cell recorded for this study was done randomly among all those available, it was necessary to implement a statistical model with a factor corresponding to this random effect. The statistical analyses were carried out using the 'linear mixed effect' (lme version 3.1-128) routine (Pinheiro et al. 2016 ). The lme model was subsequently tested using an ANOVA (ANOVA.lme) followed by a post hoc Dunn's multiple comparisons test. Wherever an interaction between the variables and the conditions was statistically significant we reported the P value. In the statistical analysis, the differences were considered significant when P < 0.05. Figures were prepared and finalised using CorelDraw 2018 (Corel Corporation, Ottawa, ON, Canada).
Results
CSF-cNs express the B 1 subunit of the GABA B receptor
A previous publication has shown a strong labelling for GABA B1 subunits in cells of rat spinal cord with morphological hallmarks of CSF-cNs, that is a small round cell body with a single process extending toward the CC (Margeta-Mitrovic et al. 1999) . To confirm that GABA B1 is expressed in CSF-cNs, we performed in the hindbrain dorsal vagal complex double immunofluorescence labelling against GABA B1 and PKD2L1 channel, a specific marker for medullospinal CSF-cNs of mouse (Orts-Del'Immagine et al. 2012 . As described previously (McDermott et al. 2001; Liu & Wong-Riley, 2005) , cell bodies with a marked immunostaining for GABA B1 subunits were observed in the dorsal motor nucleus of the vagus nerve (DMNX) and the hypoglossal nucleus (XII, Fig. 1A ; n = 3). In addition, an observation at higher magnification revealed the presence of immunoreactivity against GABA B1 subunits (arrows) in the soma of small round cells present around the CC and presenting a projection towards the CC (open arrowhead, Fig. 1B ; n = 3). These cells around the CC were positively immunolabelled by antibodies against the PKD2L1 channel, a selective marker of medullo-spinal CSF-cNs ( Fig. 1C ; n = 3). Therefore, our results indicate that medullar micrograph showing the typical morphology of CSF-cNs after whole-cell dialysis with Alexa 594 (10 μM). CSF-cNs have a round cell body and extend a dendrite ending with a bud in proximity to the CC. Scale bar, 10 μm. E, right: action potentials evoked by a 500 ms depolarising current pulse (+10 pA) in identified CSF-cNs had the same properties in controls (black trace) and in the presence of 100 μM baclofen (blue trace). F, in CSF-cNs, pressure application of 100 μM baclofen for 40 s did not induce either a hyperpolarisation under current-clamp recording (a), or an increase in the holding current under voltage-clamp mode (b). Note the single-channel activity (inset in Fb) mediated by the PKD2L1 channel, as previously described in CSF-cNs. G, in DMNX neurones, application of baclofen (100 μM, 40 s) evoked a hyperpolarisation under current-clamp recording (a), or an outward current when the cell was recorded in voltage-clamp mode (b 3.78 ± 0.67 (n = 8) 3.83 ± 0.66 (n = 7) 0.8245
In the presence of 100 μM baclofen, the resting membrane and threshold potential as well as action potentials (APs) parameters are not significantly different from control (two-tailed paired Student's t-test for all comparisons). APs were evoked by +10 pA current pulses of 500 ms duration.
CSF-cNs express GABA B1 subunits ( Fig. 1D ; n = 3). GABA B1 coexpressed with PKD2L1 in the somatodendritic compartment of CSF-cNs (arrows and open arrowheads; Fig. 1C and D; n = 3) but a clear labelling for GABA B1 was difficult to observe in the bud (closed arrowheads; Fig. 1C and D) , suggesting a low expression of the protein in the dendritic terminal protrusion. Altogether, these data suggest that medullar CSF-cNs possess GABA B -Rs.
GABA B receptors do not mediate Kir3-type potassium currents in CSF-cNs
We next investigated the functional properties of GABA B -Rs in CSF-cNs. In different neuronal models, including the hindbrain, activation of GABA B -Rs was shown to elicit Kir3-type potassium currents (GIRK). We therefore assessed whether a similar response is generated in medullar CSF-cNs. Using whole-cell patch-clamp recordings in current-clamp conditions, we showed that local application of baclofen (100 μM, for 30-40 s), a selective agonist for GABA B -Rs, changed neither the properties of APs evoked by a depolarising current pulse ( Fig. 1E and Table 1 ) nor the CSF-cN intrinsic properties (Table 1) . Further, at a holding potential of −50 mV, in all CSF-cNs tested, baclofen activation of GABA B receptors failed to elicit either a hyperpolarisation of the resting membrane potential (RMP, current-clamp recording, Fig. 1Fa ; n = 10) or an increase in the holding current (voltage-clamp recording, Fig. 1Fb ; n = 22). Since DMNX neurones also express GABA B -Rs (Fig. 1A) and were shown to have GABA B -mediated potassium currents (Browning & Travagli, 2001 ), we tested, as an internal control in the same slice preparation, whether GABA B -R-mediated response can be recorded. In all DMNX neurones, pressure application of baclofen (100 μM, 40 s) induced a hyperpolarisation of the membrane potential by 9.45 ± 4.12 mV in current-clamp mode ( Fig. 1Ga ; n = 6) or an outward potassium current under voltage-clamp mode with an average amplitude of 23.67 ± 25.21 pA ( Fig. 1Gb ; n = 6). Both responses were fully blocked in the presence of CGP54626A (CGP), a GABA B -R selective antagonist ( Fig. 1Ga and Gb; n = 3).
These data show that GABA B -Rs activate Kir3-type potassium channels in DMNX neurones but not in CSF-cNs.
Characterisation of voltage-gated calcium channels in CSF-cNs
In juvenile rats, CSF-cNs were suggested to express calcium voltage-dependent channels (Ca V ) (Marichal et al. 2009 ) but so far, no functional data are available in adult mice and the type of Ca V expressed is unknown. To address this point in our model, we carried out voltage-clamp recordings in conditions enabling selective isolation of the Ca 2+ current (see Methods, Recording of voltage-gated calcium currents) and applied voltage steps (V step from −60 to +30 mV, 10 mV increments) for 100 ms from a holding potential of −70 mV to evoke inward currents of increasing amplitude ( Fig. 2A) . The evoked currents exhibit fast activation at the start of the voltage steps followed by a sustained current showing little inactivation and ending with a fast tail current. As illustrated from the average current-voltage relationship (I-V curve, Fig. 2B ) and the fit of the experimental data using a Boltzmann function (red line in Fig. 2B ), the current activates for membrane potentials more depolarised than −40 mV, reaches a peak amplitude of −129.72 ± 54.91 pA at a membrane potential of +11.60 ± 0.43 mV ( Fig. 2B ; n = 13). These properties of the recorded current are in agreement with those reported for high voltage activated Ca 2+ currents (Catterall, 2011) and this assumption is confirmed by the full block of the current observed in the presence of 200 μM cadmium (Cd 2+ ), a selective blocker of Ca V (peak current amplitudes: −177.00 ± 38.36 pA in control and +7.25 ± 21.32 pA in Cd 2+ ; Fig. 2C , n = 12; P < 0.01, Wilcoxon matched-pairs signed ranked test). Next, we characterised the nature of Ca V expressed by CSF-cNs and underlying the observed current using selective toxins or inhibitors for the principal Ca V subtypes. In the presence of 500 nM ω-conotoxin GVIA (ω-CnTx GVIA), a selective blocker for Ca V 2.2 (or N-type Ca 2+ channels), the amplitude of the recorded current was strongly reduced (peak current amplitudes: −141.71 ± 19.59 pA in control and -52.57 ± 28.14 pA in ω-CnTx A B C Figure 2 . CSF-cNs express N-type voltage-gated Ca 2+ channels A, representative whole-cell current traces recorded in response to voltage steps from −60 mV to +30 mV (V Step , +10 mV increments, protocol illustrated under the current traces) from a holding potential of −70 mV (V h ) to elicit Ca 2+ current in a CSF-cN. The inset represents the recorded CSF-cN after cell dialysis with Alexa 594 (10 μM) to confirm the morphology. CC: central canal. B, average current-voltage relationship for the Ca 2+ currents recorded in CSF-cNs (n = 13). Data are fitted using a Boltzmann function (red trace, see Methods for more details). The inset in red gives the values defining the properties of the Ca 2+ current in CSF-cNs obtained from the Boltzmann fit of the average data (see text for details). C, summary box-and-whiskers plots of the averaged percentage of Ca 2+ current blockade in the presence of cadmium (Cd 2+ ; 105 ± 3%; black box, n = 12), ω-conotoxin GVIA (ω-CnTx GVIA; 64 ± 6%; grey box, n = 7), ω-agatoxin IVA (ω-AgaTx IVA; 11 ± 2%, light grey box, n = 11), and nifedipine (14 ± 3%; white box, n = 9). Ca 2+ GVIA + ; Fig. 2C , n = 12; P < 0.05, Wilcoxon matched-pairs signed ranked test). In contrast, in the presence of 500 nM ω-agatoxin IVA (ω-AgaTx VIA), a blocker of Ca V 2.1 (P/Q type), or 1 μM nifedipine, a blocker of Ca V 1.2 and 1.3 (neuronal L type), there was only a small decrease in the Ca 2+ current amplitude (peak current amplitudes: −162.64 ± 75.60 pA in control and −144 ± 60.84 pA in ω-AgaTx VIA, n = 11; −123.17 ± 49.39 pA in control and -97.33 ± 29.37 pA in nifedipine, n = 6; P < 0.01 and P < 0.05, respectively, Wilcoxon matched-pairs signed ranked test). Taken together, our results demonstrate that medullar CSF-cNs express functional voltage-dependent Ca 2+ channels that are primarily of the Ca V 2.2 type (N type).
GABA B receptors are functional in CSF-cNs and modulate voltage-gated calcium channels
Classically GABA B -R activation has been shown to inhibit Ca V both at pre-and postsynaptic levels and therefore to modulate cellular activity and synaptic transmission (see below), respectively. To assess whether GABA B -Rs activation modulates Ca V in CSF-cNs, we elicited peak Ca 2+ currents (holding potential of −70 mV, voltage step to +10 mV) and tested the effect of baclofen on the current amplitude. Figure 3A and B illustrates representative traces showing the effect of baclofen on Ca 2+ current recorded in two CSF-cNs in the absence and presence of CGP. In all tested CSF-cNs, baclofen application (100 μM, for 30 s) induced a rapid and long-lasting inhibition of Ca 2+ currents ( Fig. 3C and D ; n = 13) that slowly reversed upon baclofen wash out. In the presence of CGP, the baclofen-mediated Ca 2+ current inhibition was strongly reduced ( Fig. 3A-D; n = 14) .
G protein coupled receptors (GPCR) of the Gα i/o type primarily inhibit Ca 2+ current through the direct binding of the Gβγ subunits to the channel. This inhibition is voltage dependent and can be removed by a strong depolarisation (Herlitze et al. 1996; Ikeda, 1996) . To test whether the observed effect on Ca 2+ currents following GABA B -R activation is mediated through a similar mechanism in CSF-cNs, we used the classical triple pulse protocol (see Methods, Recording of voltage-gated calcium currents). In controls, the Ca 2+ current elicited by the prepulse and the postpulse had similar average amplitudes of −176.83 ± 99.62 pA and −149.43 ± 65.48 pA, respectively ( Fig. 4Aa ; n = 9, P = 0.3719 prevs. postpulse amplitude in control, ANOVA.lme/post hoc Dunn's multiple comparison test) and the pre/postpulse current sensitivity to cadmium and ω-CnTx GVIA is significantly higher compared to that observed in the presence of ω-agatoxin IVA ( * * * * P < 0.0001, * * P < 0.01; Kruskal-Wallis/Dunn's post hoc multiple comparison test). [Colour figure can be viewed at wileyonlinelibrary.com] J Physiol 597.2 ratio was around 95% (Fig. 4D ; n = 9). As illustrated for a representative recording (Fig. 4Aa and Ba), baclofen application strongly reduced the peak amplitude of the Ca 2+ current activated during the prepulse (average peak amplitude: −61.76 ± 44.41 pA, n = 9; ANOVA.lme/post hoc Dunn's test, P < 0.0001 compared to control; see above; (1) in Fig. 4Aa, Ba, C and D) . Note that the level of inhibition was similar to that reported in Fig. 3 (inhibition: 51 ± 24%; n = 13, in Fig. 3D for single pulse protocol; 52 ± 24%; n = 9, in Fig. 4D for triple pulse protocol; Mann-Whitney test, P = 0.8409). However, following the depolarisation to +100 mV, the current inhibition mediated by baclofen was strongly reduced for the postpulse compared to the prepulse in the same conditions and the average peak amplitude was similar to that observed for the postpulse recordings in controls (control postpulse: −149.43 ± 65.48 pA; baclofen postpulse: −114.66 ± 63.99 pA, P = 0.078 and prepulse vs. postpulse in baclofen, P < 0.01, ANOVA.lme/post hoc Dunn's multiple comparison test; n = 9; (2) in Fig. 4Aa , Ba and C; n = 9). Accordingly, the pre/postpulse ratio decreased by around 40% compared to the control situation ( Fig. 4D ; n = 9). In the presence of CGP, the inhibition of the Ca 2+ current by baclofen was strongly reduced for the current elicited by the pre-and postpulse (average peak amplitude: −179.59 ± 72.86 pA and −166.84 ± 79.71 pA for the prepulse (P = 0.9591) and −154.22 ± 60.94 pA and −144.32 ± 59.82 pA for the postpulse (P = 0.9901) in CGP in the absence or presence of baclofen, respectively, n = 10; P = 0.0703 and 0.9801 for the pre-and postpulse in baclofen in the absence (n = 9) or presence (n = 10) of CGP; ANOVA.lme/post hoc Dunn's multiple comparison test; see (2) in Fig. 4Ab , Bb, and C). In the presence of CGP alone and with baclofen, the pre/postpulse ratio was similar to that observed in control and close to 100% ( Fig. 4D ; n = 10). Altogether, these results show that GABA B -Rs are functional in CSF-cNs and inhibit Ca 2+ current through a Gβγ-mediated effect. . GABA B receptors inhibit voltage-gated Ca 2+ channels through a Gβγ-mediated mechanism A, representative traces illustrating the peak Ca 2+ current recorded in two CSF-cNs in control (a) or in the presence of 2 μM CGP (b) using a triple pulse protocol where 2 voltage steps to +10 mV (50 ms) from a holding potential of −70 mV are applied and separated by a depolarising step to +100 mV for 50 ms. The recording protocol is illustrated below the traces in panel a and the pulses before and after the depolarisation to +100 mV represent the prepulse (black font) and postpulse (grey font), respectively. Aa, current traces recorded in control (black trace) in the presence of baclofen (blue trace) and elicited by the prepulse (1) and the postpulse (2). Ab, recordings in the presence of 2 μM CGP before (red trace) and during baclofen application (violet trace) for the prepulse (1ʹ) and the postpulse (2ʹ). B, time course of the Ca 2+ current peak amplitude for the neurones illustrated in Aa and Ab and illustrating the baclofen effect on the amplitude of the Ca 2+ current elicited by the prepulse (a) and the postpulse (b) in the absence (1 and 2, blue circles) and the presence of 2 μM CGP (1ʹ and 2ʹ, red circles). Baclofen was pressure applied at 100 μM for 30 s as indicated by the blue bars. C, summary box-and-whiskers plots for the Ca 2+ current inhibition induced by baclofen in the absence (blue box) and presence (violet box) of 2 μM CGP for the prepulse (open box) and the postpulse (grey box) as indicated above the graph. Baclofen produced a significant inhibition of the peak Ca 2+ current amplitude elicited by the prepulse that was larger than that observed for the postpulse Ca 2+ current (baclofen: 52 ± 24% for the prepulse and 19 ± 8% for the postpulse, n = 9). In the presence of CGP, the baclofen inhibitory effect was strongly and significantly reduced and there was no significant difference between the inhibition observed for the pre-and postpulse currents (baclofen in CGP: 4 ± 12% for the prepulse and 3 ± 7% for the postpulse, n = 10). D, summary box-and-whiskers plots for the prepulse/postpulse ratio recorded in control (black box), in baclofen (blue open box), in CGP (red open box) and in baclofen with CGP (violet open box). In the presence of baclofen alone, the prepulse/postpulse ratio was strongly reduced (control: 98 ± 6%, baclofen: 62 ± 27%, n = 9). In the presence of CGP, baclofen failed to reduce the prepulse/postpulse ratio (CGP: 102 ± 11%, baclofen in CGP: 103 ± 14%, n = 10; P = 0.9998). The prepulse/postpulse ratios calculated in the presence of CGP and baclofen with CGP were both significantly higher than that calculated for baclofen alone (see above; * * * * P < 0.0001 for the ratio with baclofen alone compared to CGP alone and CGP with baclofen, respectively). Fig. 5A and B; In the presence of baclofen alone, the net increase in fluorescence was significantly reduced while that effect was abolished when CGP was bath applied (control: 282 ± 51% and baclofen: 166 ± 35%, n = 6; CGP: 429 ± 170% and baclofen in CGP: 379 ± 158%, n = 7; * * P < 0.01, * P < 0.05, ANOVA.lme/Dunn's post hoc multiple comparison test). D, summary box-and-whiskers plots for the decrease in the normalised fluorescence rise recorded after the 5th train of APs in the presence of baclofen alone (open blue box, n = 6) and in the presence of baclofen with CGP (open violet box, n = 7). In the presence of CGP, the decrease in the recorded fluorescence rise was significantly reduced (baclofen alone: 40 ± 15%, n = 6; baclofen in CGP: 9 ± 18%, n = 7; * P < 0.05, Mann-Whitney test). [Colour figure can be viewed at wileyonlinelibrary.com] from baseline on the 5 th train ( Fig. 5Aa and B ; n = 12). This [Ca 2+ ] i elevation corresponded to 292 ± 70% when normalised to the increase recorded for the 1st AP train ( Fig. 5C ; n = 12). At the end of the 5 th train of APs, the [Ca 2+ ] i slowly decreased in an exponential manner to return after several seconds to a value similar to the baseline value (3 in Fig. 5A and B) . As illustrated in Fig. 5Ab and B for a representative recording, in the presence of baclofen, the amplitude of the [Ca 2+ ] i elevation, recorded on the 5 th train of APs, was reduced by nearly half ( Fig. 5C  and D ; n = 6). We reproduced the same protocol in the presence of CGP and, in 7 out of 9 cells recorded, baclofen application failed to reduce the [Ca 2+ ] i elevation ( Fig. 5C  and D ; n = 7). Our results, therefore, indicate that CSF-cN depolarisation following a train of APs induces an elevation of [Ca 2+ ] i through activation of Ca V 2.2 and that GABA B -R activation leads to a reduction in this rise.
Inhibitory synaptic transmission is modulated by GABA B receptors in CSF-cNs
Activation of GABA B -Rs inhibits synaptic transmission by acting on voltage-gated calcium channels at a variety of central synapses. Therefore, we studied in CSF-cNs the effect of baclofen on postsynaptic inhibitory (IPSCs) and excitatory synaptic currents (EPSCs) evoked by local electrical stimulation. Our previous work has demonstrated the presence of spontaneous inhibitory synaptic transmission (Orts-Del'Immagine et al. 2012) but electrically evoked IPSCs have never been recorded in CSF-cNs. Thus, we first characterised evoked IPSCs in medullar CSF-cNs. In the presence of DNQX (20 μM) and strychnine (1 μM) to block respectively glutamatergic and glycinergic receptors, electrical stimulation (50−60 V, 100 μs) at a frequency of 0.1 Hz elicited postsynaptic inward currents in CSF-cNs voltage-clamped at −60 mV ( Fig. 6Aa and b) . Postsynaptic inward currents were reversibly reduced by bath application of gabazine, (GBZ, 10 μM), a selective GABA A receptor antagonist, with a percentage of inhibition of 98 ± 6% (Fig. 6Aa, Ab and B ; n = 10). In addition, the reversal potential of postsynaptic inward currents determined by measuring the current amplitudes at different holding potentials from −60 to +40 mV (with 20 mV increments) was −9.75 ± 3.15 mV ( Fig. 6C and D ; n = 6), which is close to the calculated equilibrium potential for chloride ions (+3.2 mV). These results show that evoked IPSCs recorded in CSF-cNs were mediated by GABA A receptors. We next checked whether baclofen has an inhibitory effect on evoked IPSCs. Bath application of the selective GABA B receptor agonist baclofen (100 μM) powerfully reduced the amplitudes of evoked IPSCs recorded in CSF-cNs at a holding potential of −60 mV, with a percentage inhibition of 82 ± 12% (Fig. 6Ea , Eb and F; n = 6). The inhibitory effect of baclofen was reversed by bath application of 2 μM CGP (Fig. 6Ea, Eb and F; n = 6) . Therefore, our data show that GABA B -R activation inhibits the GABA A -dependent inhibitory synaptic transmission in CSF-cNs.
GABA B receptors inhibit excitatory synaptic transmission in CSF-cNs
We previously reported that CSF-cNs express AMPA/ kainate receptors but stimulation of neurotransmitter release with a hypertonic shock did not evoke EPSCs and therefore we suggested that CSF-cNs do not receive excitatory synaptic inputs (Orts-Del'Immagine et al. 2016) . However, the mechanisms involved in the enhancement of the transmitter release by hypertonic shocks are not yet known and in neurones the enhancement is not dependent on calcium entry into presynaptic terminals (Rosenmund & Stevens, 1996; Mochida et al. 1998) . In this study, we therefore tested whether EPSCs can be induced in CSF-cNs following presynaptic calcium influx induced by electrical stimulation. In the presence of gabazine and strychnine to block, respectively, GABA A -and glycine receptor-dependent synaptic transmission, electrical stimulation (50−60 V, 100 μs) at a frequency of 0.1 Hz and from a holding potential of −60 mV induced fast postsynaptic inward currents in CSF-cNs that were reversibly inhibited by bath application of DNQX (20 μM), an AMPA/kainate receptor antagonist (Fig. 7Aa, Ab and B) . The percentage of inhibition of EPSCs by DNQX was 95 ± 6% (n = 7). Moreover, the reversal potential determined by recording postsynaptic currents at a holding potential ranging from −60 to +40 mV (20 mV increments) was 0.60 ± 7.10 mV (Fig. 7C and D, n = 5), consistent with the multiple cationic permeability of AMPA/kainate receptors. These data show that electrical stimulation evoked EPSCs mediated by AMPA/kainate receptors in CSF-cNs. We further studied the effect of GABA B -R activation on excitatory synaptic transmissions in CSF-cNs. At a holding potential of −60 mV, bath application of baclofen (100 μM) had a marked inhibitory effect on the amplitudes of EPSCs recorded in CSF-cNs, with a percentage of inhibition of 63 ± 16% (Fig. 7Ea , Eb and F; n = 7). Bath application of the antagonist CGP reversed the inhibitory effect of baclofen on EPSCs (Fig. 7Ea, Eb and F; n = 7) . These results show for the first time that CSF-cNs receive excitatory glutamatergic inputs and that activation of GABA B receptors has an inhibitory effect on the excitatory synaptic transmission.
Presynaptic action for GABA B receptor-mediated inhibition of inhibitory and excitatory synaptic transmission
We then examined whether the baclofen-mediated inhibition of EPSCs and IPSCs in CSF-cNs is caused by a pre-or postsynaptic mechanism. For this purpose, we first J Physiol 597.2 evoked synaptic responses by paired-pulse stimulation and we compared the paired-pulse ratio (PPR: amplitude of the second postsynaptic current/amplitude of the first postsynaptic current) before and during application of baclofen and CGP. At a stimulus interval of 70 ms (50−60 V, 100 μs for each pulse) and from a holding potential of −60 mV, bath application of baclofen (20 μM) significantly increased the PPR of both IPSCs (Fig. 8A and   C) and EPSCs (Fig. 8B and D) by, respectively, 65 ± 37% (n = 7) and 92 ± 70% (n = 7), largely due to a reduction in the amplitude of the first response (see lower traces in Fig. 8A and B) . Bath application of CGP (2 μM) reversed the increase in PPR induced by baclofen of both IPSCs (Fig. 8A and C) and EPSCs ( Fig. 8B and D) . To confirm further the presynaptic locus of GABA B receptor-mediated inhibition, we next checked whether there is a postsynaptic
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Eb F B C D Ab Figure 6 . Baclofen inhibits evoked inhibitory synaptic transmission in CSF-cNs A, IPSC peak amplitudes plotted versus time (a) and representative averaged traces (b) before (black trace), during (orange trace) and after (green trace) bath application of the selective GABA A receptor antagonist gabazine (GBZ, 10 μM). IPSCs were evoked every 10 s at a holding potential of −60 mV and in the presence of 20 μM DNQX (an AMPA/kainite antagonist) and 1 μM strychnine (a glycine receptor antagonist). B, box-and-whisker plots of IPSCs peak amplitudes in control and in the presence of gabazine. Gabazine had a significant inhibitory effect on IPSC amplitude (control: −71.39 ± 58.04 pA, n = 10; gabazine: −1.84 ± 5.60 pA, n = 10; * * P < 0.01, Wilcoxon matched-pairs signed rank test). C, averaged IPSCs traces in response to voltage-step applications from −60 mV to +40 mV using 20 mV increments. D, IPSC mean peak amplitudes plotted against the holding potential. The indicated reversal potential was determined from the linear regression of the current-potential relationship (R 2 = 0.99). E, time course of peak IPSCs amplitudes (a) and representative averaged traces (b) before (black trace) after bath application of 100 μM baclofen (selective agonist of GABA B receptors, blue trace) and 2 μM CGP (selective antagonist of GABA B receptors, red trace). IPSCs were evoked at 0.1 Hz and at −60 mV. F, box-and-whisker plots of IPSCs amplitudes in control and in the presence of baclofen and CGP. Baclofen significantly reduced the amplitude of IPSCs and the inhibitory effect was reversed with CGP (control: −42.82 ± 15.82 pA, n = 6; baclofen: −6.38 ± 1.97 pA, n = 6; CGP: −50.78 ± 30.12 pA, n = 6; * P < 0.05, Friedman/Dunn post hoc multiple comparison test). [Colour figure can be viewed at wileyonlinelibrary.com] interaction between GABA B receptors and GABA A or AMPA/kainate receptors by analysing the kinetics of evoked IPSCs and EPSCs, respectively. We found that application of baclofen (20 μM) did not affect either the decay time or the 10-90% rise time of IPSCs ( Fig. 8E and G) and EPSCs ( Fig. 8F and H) . Therefore, these results suggest that inhibition of both inhibitory and excitatory synaptic transmission by baclofen is mediated by activation of presynaptic GABA B receptors.
Discussion
Over the last few years, substantial advances have been made in identifying membrane proteins expressed in medullar CSF-cNs and involved in the control of their excitability. Excitation in CSF-cNs was shown to be mediated by pH sensitive PKD2L1 and ASICs channels whereas inhibition involves ionotropic GABA A and glycine receptors (Orts-Del' Immagine et al. 2012 Immagine et al. , 2016 . In EPSCs were recorded every 10 s at a holding potential of −60 mV and in the presence of gabazine (10 μM) and strychnine (1 μM). B, box-and-whisker plots of EPSCs amplitudes summarising the inhibitory effect of DNQX (control: −38.43 ± 19.51 pA, n = 7; DNQX: −1.57 ± 1.91 pA, n = 7; * * P < 0.01, Student's two-tailed paired t test). C, averaged EPSCs traces recorded at different holding potentials (from −60 to +40 mV). D, plot of the mean current amplitude of EPSC against the holding membrane potential. EPSCs had a linear relationship to holding membrane potential and linear regression analysis showed an extrapolated reversal potential close to 0 mV (R 2 = 0.99). E, EPSC peak amplitudes plotted versus time (a) and representative averaged traces (b) before (black trace) and after bath application of 100 μM baclofen (blue trace) and 2 μM CGP (red trace). EPSCs were evoked at 0.1 Hz and at −60 mV. F, summary box-and-whisker plots showing the effect of baclofen on EPSC amplitudes. Baclofen had a significant inhibitory effect on EPSC amplitudes that was reversed with CGP (control: −37.96 ± 10.64 pA, n = 7; baclofen: −14.86 ± 9.79 pA, n = 7; CGP: −37.59 ± 12.99 pA, n = 7; * * * * P < 0. 2+ . Our study further shows, for the first time in rodents, that CSF-cNs have AMPA/kainate receptors that are engaged in a synaptic transmission, which demonstrates that CSF-cNs receive an additional excitatory control through glutamatergic inputs. Finally, we found that GABA B receptors are located presynaptically on both GABAergic and glutamatergic terminals and their activation inhibits the release of GABA and glutamate onto CSF-cNs. The schematic illustration in Figure 9 summarises the overall results.
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Absence of GIRK-dependent inhibition in CSF-cNs
The most intriguing result reported here is the lack of GABA B -mediated GIRK response in CSF-cNs. Indeed, our data revealed that the application of baclofen, the selective agonist of GABA B -Rs, had no effect in all cells tested, . D, summary box-and-whisker plots showing that baclofen significantly increased the paired-pulse ratio of EPSCs (PPR: amplitude of the second EPSC/amplitude of the first EPSC). The baclofen-mediated increase of the PPR was reversed with CGP (control: 0.85 ± 0.40, n = 7; baclofen: 1.52 ± 0.73, n = 7; CGP: 0.86 ± 0.43, n = 7: * * P < 0.01, repeated measures ANOVA/Tukey post hoc multiple comparison test). E and F, summary box-and-whisker plots showing that IPSCs (E) and EPSCs (F) had similar decay times between control (IPSC: 22.35 ± 3.01 ms, n = 11; EPSC: 2.71 ± 0.50 ms, n = 9) and 20 μM baclofen (IPSC: 23.07 ± 3.26 ms, n = 11; P = 0.5305, Student's two-tailed paired t test; EPSC: 2.82 ± 0.48 ms, n = 9; P = 0.6106, Student's two-tailed paired t test). For both IPSCs and EPSCs, decay time constants were obtained from a monoexponential fit to the decay phase of synaptic currents. G and H, box-and-whisker plots summarising the effect of baclofen (20 μM) on the 10-90% rise time of evoked IPSCs (G) and EPSCs (H). Baclofen had no significant effect on the 10-90% rise time of IPSCs (control: 1.68 ± 0.55 ms, n = 11; baclofen: 1.68 ± 0.63 ms, n = 11; P = 0.9810, Student's two-tailed paired t test) and EPSCs (control: 0.79 ± 0.25 ms, n = 9; baclofen: 0.89 ± 0.63 ms, n = 9; P = 0.6065, Student's two-tailed paired t test (Browning & Travagli, 2001) , which rules out eventual bias in our recording conditions of GIRK responses. Postsynaptic GABA B -Rs express after birth but they do not open GIRK channels in developing brain in the first days of life (Gaiarsa & Porcher, 2013) . GABA B -Rmediated GIRK currents establish in brain rodents after the first postnatal week (Luhmann & Prince, 1991; Gaiarsa et al. 1995) or at the latest between the third and the fifth postnatal week (Nurse & Lacaille, 1999; Lei & McBain, 2003) . In our study, we recorded CSF-cNs in 8-to 12-week-old adult mice, therefore in a time window in which GABA B -Rs are supposed to be fully mature and trigger GIRK currents. However, CSF-cNs were shown to retain some immature features in adulthood because they continue to exhibit immature markers such as the expression of doublecortin or Nkx6.1 proteins, as well as a high resting potential and input resistance (Orts-Del'Immagine et al. 2012 , 2017 . As GIRK inhibition has been shown to appear in mature neurones (Mongiat et al. 2009; Gonzalez et al. 2018) , one could suggest that the lack of GABA B -R-mediated GIRK inhibition in CSF-cNs is the consequence of their persistent immature state. The physiological conditions in which CSF-cNs terminate their development, as well as the underlying mechanisms, are still unknown, but the expression of GIRK inhibition concomitantly with the full maturation of CSF-cNs may strongly change their excitability properties (Mongiat et al. 2009 ). Interestingly, in developing brain regions where GABA B -Rs do not control cell excitability by gating GIRK channels, it was shown that the receptor is coupled to signalling pathways involved in neuronal development (Bony et al. 2013; Gaiarsa & Porcher, 2013; Giachino et al. 2014) . One could therefore hypothesise that GABA B -Rs might be involved in maturation processes of CSF-cNs, but further studies will need to address this potential function for GABA B -Rs in CSF-cNs.
CSF-cNs express voltage-gated Ca
+ channels and they are inhibited by GABA B receptors
To date there is little information about the Ca V expression and function in medullo-spinal CSF-cNs, nor about the isoform(s) expressed. Classically, depending on the α-subunit forming the channel, Ca V can be subdivided in high (Ca V 1 and 2) and low voltage-activated (Ca V 3) channel classes comprising different isoforms based on channel electrophysiological properties (Catterall, 2011) . Here, using a selective pharmacological approach, we conducted the first characterisation of Ca V expression in CSF-cNs from adult mice. Our results indicate that CSF-cNs express primarily the N-type Ca 2+ channels (Ca V 2.2; around 80% of the total current) along with Ca V 2.1 (P/Q-type) and Ca V 1.2 and 1.3 (neuronal L-type), although at a lower level (<20% of the total current). All identified isoforms are the neuronal forms of high-voltage activated Ca 2+ channels (Catterall, 2011) , a result consistent with the neuronal nature of CSF-cNs. Marichal and colleagues (2009) indicated that CSF-cNs recorded from juvenile rats express T-type Ca 2+ channels (Ca V 3). This subtype is characterised by an activation around −60 mV (low-voltage) and a fast inactivation around −40 mV (Fox et al. 1987; Ikeda & Dunlap, 2007; Catterall, 2011) . Our results suggest that CSF-cNs from adult mice do not express the Ca V 3 subtype. Indeed, in adult mouse CSF-cNs, Ca 2+ currents could only be activated for membrane potentials higher than -40 mV and we did not observe in the current-voltage relationships the characteristic shoulder (between −60 and -40 mV) underlying Ca V 3 activation.
The characterisation of Ca V subtypes expressed in CSF-cNs and the analysis of their modulation following GABA B -R activation typically required 10 min long recordings, a period over which we observed a decrease in the Ca 2+ current amplitude by 35.8 ± 9% (n = 13), even in the presence of 10 mM intracellular EGTA as Ca 2+ buffer (slow kinetics), while the access resistance and the holding current remained unchanged over the same period of time (data not shown). Calcium currents have been reported to undergo rundown when recorded over long periods in the whole-cell configuration and this phenomenon is largely due to a Ca 2+ -dependent mechanism (Belles et al. 1988 ). In the presence of 10 mM BAPTA, another type of Ca 2+ buffer with faster binding kinetics and higher buffering capacity, we observed a similar phenomenon (amplitude decreased by 24.2 ± 4%, n = 11; P = 0.706 when compared to recordings with EGTA, Mann-Whitney test; data not shown). This result would suggest that the observed rundown is not Ca 2+ dependent and would involve some other regulatory processes. On the other hand, CSF-cNs are small neurones (ß10 μm diameter) with little cytosolic space, and one could suggest that recordings performed under whole-cell configuration would lead to massive dialysis of intracellular compounds necessary for Ca 2+ channel activity. To characterise the molecular basis of the observed rundown, one would need to carry out a set of specific experiments but, since this is beyond the scope of the present study, it was not further addressed.
In the past decades, numerous studies have demonstrated that Ca 2+ channels, especially Ca V 2.2 in neurones, are inhibited by activation of metabotropic receptors primarily of the G i/o type (Pertussis toxin sensitive) (Ikeda & Dunlap, 1999 , 2007 Dolphin, 2003) through the direct binding to the channel of the Gβγ dimers (Bean, 1989; Ruiz-Velasco & Ikeda, 2000; Dolphin, 2003; Zamponi & Currie, 2013) . Medullar CSF-cNs receive GABAergic synaptic entries that would activate both synaptic ionotropic GABA A and metabotropic GABA B receptors. The latter GABAergic receptor subtype was shown in different neuronal populations to inhibit both pre-and postsynaptic Ca 2+ channels (Pérez-Garci et al. 2006; Booker et al. 2018) . Consistent with the literature, we demonstrate in medullar CSF-cNs that GABA B -Rs strongly and selectively inhibit Ca V 2.2 and we show that this inhibition is mediated by a voltage-dependent Gβγ mechanism. As a consequence, GABA B -R-mediated Ca V inhibition leads to a decrease in the Ca 2+ influx and thus in the intracellular Ca 2+ concentration. Except for its role in triggering neurotransmission, Ca 2+ plays crucial functions in the regulation of neuronal physiology and activity. First, at the genomic level, Ca 2+ was shown to stimulate Ca 2+ -regulated-kinase-cascades and phosphorylation of AMP-response element binding protein (CREB) and to play a role in gene transcription (Gallin & Greenberg, 1995; West et al. 2001) . Thus, variation in intracellular Ca 2+ might recruit basal transcription machinery in CSF-cNs, leading to an activity-dependent protein expression. Second, several reports indicate that Ca 2+ is capable of activating or modulating sodium, potassium (Shah et al. 2006) and chloride (Frings et al. 2000) ionic conductance and/or of regulating postsynaptic receptors through Ca 2+ -dependent phosphorylation processes (Booker et al. 2018) . Similar mechanisms might exist in CSF-cNs to regulate their activity and excitability. Finally, PKD2L1 channels were shown to be regulated by intracellular Ca 2+ (Chen et al. 1999; DeCaen et al. 2016) and to act as a sensory receptor modulating CSF-cN excitability (Orts-Del'Immagine et al. 2016; Jalalvand et al. 2016) . Thus, in CSF-cNs, variation in intracellular Ca 2+ would affect PKD2L1 activity and in turn CSF-cN excitability. Considering that GABA B -R activation reduces Ca 2+ influx in CSF-cNs, one would expect a reduced activation or stimulation of the previously mentioned signalling cascades and, as a consequence, a modulation of CSF-cN activity and physiology. Similarly, bioactive compounds circulating in the CSF or released by synaptic partners might activate other GPCR subtypes expressed in CSF-cNs and targeting Ca 2+ signalling to regulate CSF-cN activity. The identification of such regulatory pathways represents one of the future challenges in the demonstration for the role and modulation of medullo-spinal CSF-cNs in the central nervous system.
CSF-cNs receive synaptic glutamatergic inputs
As the spontaneous synaptic activity is very low in rodent CSF-cNs, we used in our previous works the application of a hypertonic solution to increase the synaptic release of neurotransmitters and found that hypertonic shocks induce in CSF-cNs inhibitory GABA A and glycinergic synaptic currents, but not excitatory glutamatergic synaptic currents (Orts-Del'Immagine et al. 2012 . In neurones, the mechanisms underlying the increase of synaptic release following hypertonic shocks are not well known and more importantly they do not involve calcium entry into the presynaptic compartment (Rosenmund & Stevens, 1996; Mochida et al. 1998) . For a more accurate analysis of synaptic transmission, we therefore used in this study a physiologically relevant approach using electrical stimulations to evoke calcium-dependent synaptic transmission. We found that local electrical stimulations indeed evoked in CSF-cNs glutamatergic synaptic currents (EPSCs), showing that, in addition to GABAergic and glycinergic synaptic inputs, CSF-cNs receive also functional glutamatergic synaptic inputs. Evoked EPSCs were almost fully inhibited by DNQX, a selective antagonist of AMPA/kainate receptors, indicating that EPSCs in CSF-cNs do not have a NMDA receptor component. These results are consistent with our previous data showing that CSF-cNs express functional kainate and AMPA receptors but not NMDA receptors (Orts-Del'Immagine et al. 2016) . Indeed, currents evoked by local application of glutamate in medullar CSF-cNs were inhibited by DNQX but not by the NMDA receptor antagonist AP-V and application of NMDA failed to induce any currents, even at more depolarised potentials to remove the magnesium block (Orts-Del' Immagine et al. 2016) . Note that spinal CSF-cNs in lower vertebrates such as lampreys have been shown to exhibit glutamatergic transmission engaging both AMPA and NMDA receptors (Jalalvand et al. 2016) . Whether this difference is the consequence of NMDA receptor loss of expression in mammalian CSF-cNs during evolution or more simply a different glutamatergic signalling between CSF-cNs localised in brainstem and spinal cord remains an open question.
GABA B receptors inhibit both the release of GABA and glutamate onto CSF-cNs
We demonstrated that activation of GABA B -Rs by baclofen inhibits the amplitude of evoked IPSCs and EPSCs recorded in CSF-cNs. The inhibitory effect of baclofen on the synaptic transmission in CSF-cNs is most likely mediated by the activation of GABA B -Rs located presynaptically on terminals of GABAergic and glutamatergic inputs and by interfering with the neurotransmitter release machinery, as shown in many brain regions (Pinard et al. 2010) . Two results in our study support this assumption. First, we show that baclofen enhanced the paired-pulse ratio of two consecutives IPSCs or EPSCs, an observation consistent with an alteration of the neurotransmitter release probability, as reported in a variety of different synapses (Manabe et al. 1993; Wilcox & Dichter, 1994; Fioravante & Regehr, 2011) . Second, we show that baclofen had no effects on IPSC and EPSC kinetics (rise and decay times), therefore ruling out eventual interactions between postsynaptic GABA B -Rs and postsynaptic GABA A or AMPA/kainate receptors. Studying the effect of baclofen on the frequency of miniature IPSCs and EPSCs would be a suitable approach to further confirm the presynaptic terminal localisation of GABA B -Rs on GABAergic and glutamatergic inputs to CSF-cNs. However, such experiments would be difficult to achieve in CSF-cNs since the frequency of spontaneous synaptic events is very low in these neurones (Orts-Del'Immagine et al. 2012 .
Conclusion
In the present study, we characterise for the first time in mouse medullar CSF-cNs their synaptic connectivity and show that they receive both GABAergic and AMPA/kainate glutamatergic inputs. Further we indicate that GABA B -Rs are functional and act as modulators of CSF-cN activity both at the pre-and postsynaptic level where they target Ca 2+ channels. These results add to the growing bulk of data on CSF-cN physiology and give the first insights into CSF-cN regulation through synaptic partners. In future studies, one will first need to identify the localisation of the GABAergic and glutamatergic neuronal partners connected to medullar CSF-cNs and to determine how they modulate their activity. It will then be necessary to identify whether they receive synaptic projections from other neuronal populations. Together, the expected results of these studies will form a basis for understanding the function of this unique neuronal population.
